Wolinsky JS - Search Results

1

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.

Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS. Johnson KP, et al. Among authors: wolinsky js. Mult Scler. 2000 Aug;6(4):255-66. doi: 10.1177/135245850000600407. Mult Scler. 2000. PMID: 10962546 Clinical Trial.

2

Progressive multifocal leukoencephalopathy: clinical pathological correlates and failure of a drug trial in two patients.

Wolinsky JS, Johnson KP, Rand K, Merigan TC. Wolinsky JS, et al. Trans Am Neurol Assoc. 1976;101:81-2. Trans Am Neurol Assoc. 1976. PMID: 1028274 No abstract available.

3

Cerebrospinal-fluid lymphocyte populations and immune complexes in active multiple sclerosis.

Coyle PK, Brooks BR, Hirsch RL, Cohen SR, O'Donnell P, Johnson RT, Wolinsky JS. Coyle PK, et al. Among authors: wolinsky js. Lancet. 1980 Aug 2;2(8188):229-32. doi: 10.1016/s0140-6736(80)90121-x. Lancet. 1980. PMID: 6105395

4

Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group.

Zhao GJ, Li DK, Wolinsky JS, Koopmans RA, Mietlowski W, Redekop WK, Riddehough A, Cover K, Paty DW. Zhao GJ, et al. Among authors: wolinsky js. J Neuroimaging. 1997 Jan;7(1):1-7. doi: 10.1111/jon1997711. J Neuroimaging. 1997. PMID: 9038425 Clinical Trial.

5

Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis.

Brod SA, Kerman RH, Nelson LD, Marshall GD Jr, Henninger EM, Khan M, Jin R, Wolinsky JS. Brod SA, et al. Among authors: wolinsky js. Mult Scler. 1997 Feb;3(1):1-7. doi: 10.1177/135245859700300101. Mult Scler. 1997. PMID: 9160341 Clinical Trial.

6

T cell-T cell activation in multiple sclerosis.

Lindsey JW, Kerman RH, Wolinsky JS. Lindsey JW, et al. Among authors: wolinsky js. Mult Scler. 1997 Aug;3(4):238-42. doi: 10.1177/135245859700300404. Mult Scler. 1997. PMID: 9372506

7

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS. Johnson KP, et al. Among authors: wolinsky js. Neurology. 1998 Mar;50(3):701-8. doi: 10.1212/wnl.50.3.701. Neurology. 1998. PMID: 9521260 Clinical Trial.

8

The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS. Goodin DS, et al. Among authors: wolinsky js. Neurology. 1999 Jun 10;52(9):1737-45. doi: 10.1212/wnl.52.9.1737. Neurology. 1999. PMID: 10371517 No abstract available.

9

Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis.

Brod SA, Lindsey JW, Wolinsky JS. Brod SA, et al. Among authors: wolinsky js. Ann Neurol. 2000 Jan;47(1):127-31. Ann Neurol. 2000. PMID: 10632113

10

Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators.

Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC. Noseworthy JH, et al. Among authors: wolinsky js. Neurology. 2000 May 9;54(9):1726-33. doi: 10.1212/wnl.54.9.1726. Neurology. 2000. PMID: 10802775 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

305 results

Search Page

Filters